XML 30 R18.htm IDEA: XBRL DOCUMENT v3.20.2
ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - (Tables)
 9 Months Ended
Sep. 30, 2020
Accounting Policies [Abstract]  
Schedule of Revenue from Strategic Partnering Collaboration Agreements and Research Activity Grants as a Percentage of Total Revenues
Revenues from major collaboration agreements and research activity grants as a percentage of total revenues were as follows:
Three Months Ended September 30,Nine Months Ended September 30,
2020201920202019
Pfizer68 %16 %51 %11 %
Biogen16 %— 19 %— 
Kite Pharma, Inc.13 %40 %24 %55 %
Sanofi3 %40 %4 %29 %
Schedule of Cash and Cash Equivalents
A reconciliation of cash, cash equivalents and restricted cash reported within the Condensed Consolidated Balance Sheets to the amounts reported within the accompanying Condensed Consolidated Statements of Cash Flows was as follows (in thousands):
September 30,
2020		December 31,
2019		September 30,
2019		December 31,
2018
 Cash and cash equivalents$259,393 $80,428 $114,291 $140,418 
 Current restricted cash— — 2,000 — 
 Non-current restricted cash1,500 1,500 1,500 3,500 
Cash, cash equivalents and restricted cash as reported within the accompanying Condensed Consolidated Statements of Cash Flows$260,893 $81,928 $117,791 $143,918 
Restrictions on Cash and Cash Equivalents
A reconciliation of cash, cash equivalents and restricted cash reported within the Condensed Consolidated Balance Sheets to the amounts reported within the accompanying Condensed Consolidated Statements of Cash Flows was as follows (in thousands):
September 30,
2020		December 31,
2019		September 30,
2019		December 31,
2018
 Cash and cash equivalents$259,393 $80,428 $114,291 $140,418 
 Current restricted cash— — 2,000 — 
 Non-current restricted cash1,500 1,500 1,500 3,500 
Cash, cash equivalents and restricted cash as reported within the accompanying Condensed Consolidated Statements of Cash Flows$260,893 $81,928 $117,791 $143,918